Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This paper discusses topical drug delivery targeting the pilosebaceous unit for skin diseases and cosmetic purposes, emphasizing formulation choice and drug physicochemical properties but reports no new findings.

Smart microneedles improve hair loss treatment by delivering drugs precisely with fewer side effects.

This study developed a novel, 3D-printed dissolving microneedle system for delivering minoxidil to treat hair loss, which showed pH-triggered drug release and enhanced hair regrowth in an alopecia mouse model, offering a potentially sustainable and safe transdermal therapy option.

This review found that dutasteride is more effective than finasteride in increasing hair count and shaft thickness for androgenetic alopecia in men, with potential for reduced systemic side effects through mesotherapy, although further research is needed on long-term safety and dosage.

This review highlights the hair follicle's structural and functional properties as an effective route for delivering active compounds in treating hair disorders, focusing on emerging carrier technologies to enhance targeted transfollicular delivery.

This study developed a polyherbal chocolate formulation aimed at managing PCOS and hormonal balance, finding that formulation F2 showed excellent organoleptic properties and stability, with future in vivo studies being suggested.

This review examines the advances in nanostructured lipid carriers for treating hyperpigmentation but presents no new clinical results; the authors highlight their potential benefits and applications.

This report highlights Amvuttra's approval for hATTR amyloidosis as a more convenient RNAi therapy, and Olumiant's attention as the first systemic drug for hair loss among recent developments.

This study developed dissolving microneedles incorporating a new AR degrader for treating androgenetic alopecia, showing that a single application leads to superior hair regeneration compared to daily minoxidil, without systemic toxicity or androgen-related issues.

This review highlights recent advancements in microneedle technology, noting its ability to enhance transdermal drug delivery, biosensing, cancer treatment, and skin disease repair, while emphasizing its potential for improving patient compliance and reducing side effects.

This review covers follicle-targeting drug delivery systems, exploring their potential for improving localized and systemic therapies, and highlights the need for further research into follicle penetration mechanisms.

This study found that the combination of letrozole and quercetin loaded in spanlastics showed enhanced cytotoxicity and other anticancer effects against MCF-7 breast cancer cells compared to individual treatments.

This review highlights the significant impact of cutaneous and oral mucosal adverse events on patients undergoing breast cancer treatment, emphasizing the need for early detection and comprehensive management to maintain treatment adherence and enhance patient care.

This review highlights that alopecia areata is characterized by three immune endotypes, and while JAK inhibitors offer temporary control, upcoming multi-omics diagnostics and immune reprogramming strategies may achieve longer-lasting remission, according to this analysis.

This review highlights the potential of nanotechnology in enhancing the treatment of androgenetic alopecia by facilitating targeted drug delivery, improving drug stability, and increasing concentration at target sites, although clinical validation and scalable manufacturing are needed for practical implementation.

This review discusses age-related and environmental factors affecting scalp hair changes in women, highlighting diagnostic complexities and ongoing research into targeted treatments, without reporting new clinical results.

This chapter reviews ethosomes for targeted drug delivery to the scalp in androgenetic alopecia and reports no clinical results; the authors emphasize reducing systemic side effects.

In this review, researchers critically examine contemporary treatments for androgenetic alopecia, emphasizing advanced drug delivery systems, regenerative medicine, and emerging molecular targets, while identifying significant gaps that hinder translating these innovations into clinical practice.

This review evaluates existing research on topical metformin for skin conditions, reporting promising outcomes such as improved wound healing, melasma, psoriasis, acne, and alopecia, with innovative formulations like hydrogels and lipid nanoparticles enhancing its cutaneous delivery while minimizing systemic exposure.

This study developed a niosomal delivery system loaded with tretinoin and bicalutamide, optimized for follicular targeting in acne management, showing promising accumulation in hair follicles in animal models.

This study evaluated Finasteride-loaded nanostructured lipid carriers for topical use in treating androgenetic alopecia and found that these carriers offer sustained drug release and may reduce systemic side effects compared to oral administration.

This review highlights that direct drug delivery to the lungs for treating lung cancer may offer more precise targeting while reducing side effects compared to traditional methods.

This review discusses the potential use of liposomal formulations to enhance the effectiveness of cosmeceutical delivery through the skin barrier, with no new clinical results reported.

This study found that nano-transferosomal gel formulations of finasteride improved its delivery across skin layers, potentially reducing major side effects associated with oral administration for treating male pattern baldness.

A new microneedle system effectively delivers finasteride to treat hair loss.

This study found that methylcellulose-based hydrogels can effectively deliver growth hormone through the skin, with albumin increasing the hormone's permeation to 93% in simulated in vivo conditions.

This study observed that DMSO-modified liposomes enhanced the topical delivery of finasteride, improving hair follicle density and growth phase ratio in a rat model of testosterone-induced alopecia.

This study found that nanostructured lipid carriers enabled effective follicular delivery and accumulation of anti-hair loss drugs like dutasteride in mice, suggesting potential for reduced dosage frequency.

This study found that a topical formulation with nanostructured lipid carriers containing finasteride significantly restored hair follicles in androgenetic alopecia-induced rats without systemic absorption, suggesting its potential for safer and effective AGA treatment.

In this study, gelatin-coated transferosomes were developed to deliver tofacitinib specifically to hair follicles, resulting in 80% hair regrowth in alopecia areata patients with recalcitrant lesions after 12 weeks of treatment.